FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072854641> ?p ?o ?g. }

• W2072854641 endingPage "85" @default.
• W2072854641 startingPage "78" @default.
• W2072854641 abstract "Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have a very poor prognosis. However, they may achieve long-term survival by undergoing allogeneic stem cell transplantation (SCT). The purpose of this study was to assess the outcome of all adult patients with DLBCL whose treatment included a reduced-intensity conditioning (RIC) regimen for allogeneic SCT and whose data were reported in the French Society of Marrow Transplantation and Cellular Therapy registry. Sixty-eight patients (median age: 48 years) were transplanted from October 1998 to January 2007. They had received a median of 2 regimens of therapy prior to allogeneic SCT, and 54 (79%) had already undergone SCT. Prior to transplantation, 32 patients (47%) were in complete remission (CR). For all patients but 1, conditioning regimens were based on fludarabine (Flu), which was combined with other chemotherapy drugs in 50 cases (74%) and with total body irradiation (TBI) in 17 (25%). For 56 patients (82%), the donor was an HLA-matched sibling, and peripheral blood was the most widely used source of stem cells (57 patients, 84%). With a median follow-up of 49 months, estimated 2-year overall survival (OS), progression-free survival (PFS), and the cumulative incidence of relapse were 49%, 44%, and 41%, respectively. The 1-year cumulative incidence of nonrelapse mortality (NRM) was 23%. According to multivariate analysis, the patients in CR before transplantation had a significantly longer PFS and a lower CI of relapse than patients transplanted during partial remission or stable or progressive disease. These results suggest that reduced-intensity allergenic transplantation is an attractive therapeutic option for patients with high-risk DLBCL. Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have a very poor prognosis. However, they may achieve long-term survival by undergoing allogeneic stem cell transplantation (SCT). The purpose of this study was to assess the outcome of all adult patients with DLBCL whose treatment included a reduced-intensity conditioning (RIC) regimen for allogeneic SCT and whose data were reported in the French Society of Marrow Transplantation and Cellular Therapy registry. Sixty-eight patients (median age: 48 years) were transplanted from October 1998 to January 2007. They had received a median of 2 regimens of therapy prior to allogeneic SCT, and 54 (79%) had already undergone SCT. Prior to transplantation, 32 patients (47%) were in complete remission (CR). For all patients but 1, conditioning regimens were based on fludarabine (Flu), which was combined with other chemotherapy drugs in 50 cases (74%) and with total body irradiation (TBI) in 17 (25%). For 56 patients (82%), the donor was an HLA-matched sibling, and peripheral blood was the most widely used source of stem cells (57 patients, 84%). With a median follow-up of 49 months, estimated 2-year overall survival (OS), progression-free survival (PFS), and the cumulative incidence of relapse were 49%, 44%, and 41%, respectively. The 1-year cumulative incidence of nonrelapse mortality (NRM) was 23%. According to multivariate analysis, the patients in CR before transplantation had a significantly longer PFS and a lower CI of relapse than patients transplanted during partial remission or stable or progressive disease. These results suggest that reduced-intensity allergenic transplantation is an attractive therapeutic option for patients with high-risk DLBCL." @default.
• W2072854641 created "2016-06-24" @default.
• W2072854641 creator A5001526915 @default.
• W2072854641 creator A5007485886 @default.
• W2072854641 creator A5010183839 @default.
• W2072854641 creator A5011372127 @default.
• W2072854641 creator A5017332932 @default.
• W2072854641 creator A5019451763 @default.
• W2072854641 creator A5020996390 @default.
• W2072854641 creator A5025108931 @default.
• W2072854641 creator A5028385850 @default.
• W2072854641 creator A5034473496 @default.
• W2072854641 creator A5042277356 @default.
• W2072854641 creator A5045967298 @default.
• W2072854641 creator A5046391226 @default.
• W2072854641 creator A5049426974 @default.
• W2072854641 creator A5050103316 @default.
• W2072854641 creator A5052167942 @default.
• W2072854641 creator A5052502171 @default.
• W2072854641 creator A5057060048 @default.
• W2072854641 creator A5072027146 @default.
• W2072854641 creator A5072557528 @default.
• W2072854641 creator A5072757261 @default.
• W2072854641 creator A5076734375 @default.
• W2072854641 creator A5079181777 @default.
• W2072854641 creator A5082128886 @default.
• W2072854641 creator A5089841790 @default.
• W2072854641 date "2010-01-01" @default.
• W2072854641 modified "2023-10-02" @default.
• W2072854641 title "Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire" @default.
• W2072854641 cites W139931011 @default.
• W2072854641 cites W1822252547 @default.
• W2072854641 cites W1883328448 @default.
• W2072854641 cites W1945514783 @default.
• W2072854641 cites W1975390846 @default.
• W2072854641 cites W1983486168 @default.
• W2072854641 cites W1986483184 @default.
• W2072854641 cites W1990883298 @default.
• W2072854641 cites W1991149339 @default.
• W2072854641 cites W1997353354 @default.
• W2072854641 cites W1998627443 @default.
• W2072854641 cites W2011695815 @default.
• W2072854641 cites W2038880599 @default.
• W2072854641 cites W2040936606 @default.
• W2072854641 cites W2051267934 @default.
• W2072854641 cites W2052220490 @default.
• W2072854641 cites W2058015212 @default.
• W2072854641 cites W2058887761 @default.
• W2072854641 cites W2064714453 @default.
• W2072854641 cites W2068606147 @default.
• W2072854641 cites W2073140442 @default.
• W2072854641 cites W2078782557 @default.
• W2072854641 cites W2080314536 @default.
• W2072854641 cites W2085459287 @default.
• W2072854641 cites W2086571779 @default.
• W2072854641 cites W2087378865 @default.
• W2072854641 cites W2094252663 @default.
• W2072854641 cites W2121824293 @default.
• W2072854641 cites W2128237169 @default.
• W2072854641 cites W2137348614 @default.
• W2072854641 cites W2138874270 @default.
• W2072854641 cites W2139401596 @default.
• W2072854641 cites W2142867377 @default.
• W2072854641 cites W2153859516 @default.
• W2072854641 cites W2155313625 @default.
• W2072854641 cites W2327134323 @default.
• W2072854641 cites W2980145808 @default.
• W2072854641 cites W4243810912 @default.
• W2072854641 cites W64930248 @default.
• W2072854641 doi "https://doi.org/10.1016/j.bbmt.2009.09.002" @default.
• W2072854641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19744569" @default.
• W2072854641 hasPublicationYear "2010" @default.
• W2072854641 type Work @default.
• W2072854641 sameAs 2072854641 @default.
• W2072854641 citedByCount "83" @default.
• W2072854641 countsByYear W20728546412012 @default.
• W2072854641 countsByYear W20728546412013 @default.
• W2072854641 countsByYear W20728546412014 @default.
• W2072854641 countsByYear W20728546412015 @default.
• W2072854641 countsByYear W20728546412016 @default.
• W2072854641 countsByYear W20728546412017 @default.
• W2072854641 countsByYear W20728546412018 @default.
• W2072854641 countsByYear W20728546412019 @default.
• W2072854641 countsByYear W20728546412020 @default.
• W2072854641 countsByYear W20728546412021 @default.
• W2072854641 countsByYear W20728546412022 @default.
• W2072854641 countsByYear W20728546412023 @default.
• W2072854641 crossrefType "journal-article" @default.
• W2072854641 hasAuthorship W2072854641A5001526915 @default.
• W2072854641 hasAuthorship W2072854641A5007485886 @default.
• W2072854641 hasAuthorship W2072854641A5010183839 @default.
• W2072854641 hasAuthorship W2072854641A5011372127 @default.
• W2072854641 hasAuthorship W2072854641A5017332932 @default.
• W2072854641 hasAuthorship W2072854641A5019451763 @default.
• W2072854641 hasAuthorship W2072854641A5020996390 @default.
• W2072854641 hasAuthorship W2072854641A5025108931 @default.
• W2072854641 hasAuthorship W2072854641A5028385850 @default.
• W2072854641 hasAuthorship W2072854641A5034473496 @default.

• next